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Chapter
Diabetic Foot Osteomyelitis: 
Frequent Pathogens and 
Conservative Antibiotic Therapy
Nicolas Vogel, Tanja Huber and Ilker Uçkay
Abstract
Chronic diabetic foot osteomyelitis (DFO) is a frequent complication in adult 
polyneuropathy patients with long-standing diabetes mellitus. Regarding the 
conservative therapy, there are several crucial steps in adequate diagnosing and 
approaches. The management should be performed in a multidisciplinary approach 
following the findings of recent research, general principles of antibiotic therapy 
for bone; and according to (inter-)national guidance. In this chapter we emphasize 
the overview on the state-of-the-art management regarding the diagnosis and 
antibiotic therapy in DFO. In contrast, in this general narrative review and clinical 
recommendation, we skip the surgical, vascular and psychological aspects.
Keywords: Diabetic foot osteomyelitis, remission, microbiology, diagnosis,  
antibiotic therapy
1. Introduction
Patients with diabetes mellitus are at risk of complications of several organ 
systems and immunological problems of the cellular and humoral pathways [1]. 
Frequent clinical complications are diabetic foot infections, including acutely the soft 
tissues, or chronically the bone: diabetic foot osteomyelitis (DFO). In adult patients 
there is a lifetime risk of 25% for foot infections and a 15 times higher risk of lower 
limb amputation. The latter is associated with a high associated mortality risk of 
50% within five years [1, 2]. Understandably, these infections are leading to massive 
healthcare costs and antibiotic consumption [3]. In this chapter, we provide an over-
view over the current conservative (antibiotic) approach to chronic DFO; emphasiz-
ing the state-of-the-art of diagnostic procedures and antibiotic regimens for the 
conservative, internist management. To keep this chapter as short as possible, we skip 
the discussion of the different surgical procedures, diabetic foot soft tissue infections 
[4], treatment of necrosis and gangrene [5], the management of angiopathy, topical 
antibiotic use of ulcers, implant-related DFO, non-infectious complications in the 
diabetic foot [6], podiatry, or off-loading, for which a broader literature is available.
2. Pathophysiology
Several underlying mechanisms are leading to a chronic foot infection in adult 
diabetic patients [1, 7]. Of course, the immunological impairments are crucial 
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for development of all sorts of infections, but there are more important factors 
contributing to the appearance of DFO, of which the neuropathy and vasculopa-
thy are the most important cornerstones. In general, and as first step, foot ulcers 
are induced by pressure and further maceration of the skin [8]. Additionally, 
there might be a peripheral (microangiopathic) arterial disease (PAD), for which 
diabetes is an independent risk factor [9]. Wound healing may be impaired if 




In general, the diagnosis and treatment of DFO should be embedded in a 
standardized multimodal and multidisciplinary approach. The first step is the 
clinical assessment in terms of the visual presence of infection: new indura-
tion, new warmth, new redness, tenderness, purulence and/or altered pain are 
the main findings. Besides the local signs of infection, there might be systemic 
repercussions with shivering, lymphangiopathy, and sepsis. Possible additional 
signs are delayed healing or granulation, putrid smell, or wound vulnerability. 
These latter symptoms are unspecific and can also occur in other differential 
diagnoses such as ischemia, acute gout or activated Charcot neuro-arthropathy 
[11, 12]. The only pathognomonic clinical sign for the external and visual diag-
nosis of DFO is the presence of fragments of bone discharging from a wound. 
This is only possible in advanced infections related to ulcers; and it is rare. 
Often, a DFO is suspected and later confirmed. Large, deep or chronic wounds 
(persisting for ≥3 months) or red and swollen toes (“sausage toe”) raise the 
suspicion of DFO. Another simple diagnostic approach is the probe-to-bone test. 
The clinician uses a sterile blunt metal probe to determine, whether bone can be 
palpated through the diabetic foot ulcer. A negative test does not completely rule 
out DFO, while a positive test has an acceptable predictive value for deep bone 
infection [13, 14]. Although needle puncture of deep soft tissue does not reli-
ably predict the results of bone cultures, puncture of the bone itself may be an 
easy way to obtain bone culture on the ward [15]. When DFO is suspected, two 
separate positive deep bony microbiological samples showing the same bacteria 
may sometimes additionally confirm DFO [16]. One or two weeks of “antibiotic-
free window”, before biopsy or surgery, are recommended to avoid false-negative 
results [17]. In contrast, the microbiological confirmation of DFO is not neces-
sary when the infected area is amputated in toto [18]. All blood tests have no 
independent values in the mere confirmation of DFO, but might determine the 
initial, clinical severity of disease on admission.
3.2 Imaging
Upon the clinical suspicion of soft tissue infection and/or chronic ulcer in the 
polyneuropathy diabetic foot, the clinicians should also always exclude an underly-
ing DFO; at minimum with an X-ray and once at the initial assessment. The X-ray 
can also be repeated if the lesions are not improving despite adequate therapy, local 
wound care and off-loading. In a usual approach, the X-ray should be the first imag-
ing, in which signs of DFO can be detected such as osteopenia, periosteal reactions 
or erosions of the osseous borders [19, 20]. However, the overall sensitivity of the 
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plain radiography in diagnosing DFO is low. One review cited a pooled sensitiv-
ity of 0.54 and a specificity of 0.68 [21]. If the X-ray cannot provide a definitive 
radiological diagnosis, guidelines frequently recommend MRI for diagnosing DFO 
with a specificity of 79% and a sensitivity of 93% [22, 23]. However, the MRI is no 
guarantee of correct radiological diagnosis of DFO [24]. In the MRI, we may find 
focal signs on T2-weighted images and a loss of signal intensity on T1-weighted 
images. Furthermore, there is the potential to use short tau inversion recovery 
sequences (STIR), in which we see high bone signal [25–27]. What is truly ben-
eficial by using the MRI, is the possibility to detect bone marrow edema within 
1–2 days after beginning of the bone infection [28, 29]. The MRI is a diagnostic tool 
for a more accurate diagnostic of DFO. However, we lack clinical data revealing that 
DFO diagnosed by MRI would have a better outcome than those diagnosed by X-ray 
and by clinical impression alone. For this latter question, we prospectively followed 
390 DFO episodes in 186 adult patients for a median of 2.9 years and performed 
318 standard conventional X-rays (median costs 100 Swiss Francs; 100 US$) and 
with 47 (12%) MRI scans (median costs 800 US$). Among them, 18 episodes were 
associated with positive findings in the MRI only, but lacked bone lesions in the pre-
vious X-ray two to three days ago. In the database, the median duration of systemic 
antibiotics was 28 days for MRI-only episodes and 30 days for X-ray-positive cases 
and we achieved overall remission in 25% of the MRI-managed cases compared to 
27% of the cases with only a standard X-ray imaging on admission. When adjusting 
for the large case-mix, DFO episodes diagnosed by the MRI had no different remis-
sion rates [30].
3.3 Microbiological diagnostic
The microbiological diagnostic relies on specimens for culturing the involved 
pathogens. No expert recommends superficial wound swabs, because there is always 
an (inconstant) microbiome of multiple organisms in chronically open wounds. 
These superficial probes are frequently misleading, since they often represent colo-
nizing species or contaminations [12] (unless the swab originates from mere pus). 
Clinicians should always aim for several deep samples of infected (intraoperative) 
tissues or bone. An optimal specimen would be deep, infected, and still vital tissue, 
with or without pus, to catch the anaerobic pathogens [12, 31]. The microbiological 
gold standard for DFO relies on a bone biopsy, which is also feasible outside of the 
operating theater; especially in patients with polyneuropathy, who feel almost no 
pain during the bed-side sampling [25]. The accuracy of the results is increased by 
taking at least two separate bone probes. If they show the same pathogen, we usu-
ally identify the pathogen of DFO [16]. Histology has no widely-accepted criteria 
for DFO. Characteristic findings are aggregates of inflammatory cells, bone lesions, 
fibrosis, and/or reactive bone formation. As with other orthopedic infections the 
results depend on the care with which intraoperative samples are obtained (to avoid 
contamination) and whether the patient was under active antibiotic therapy [32]. 
While newer molecular laboratory methods identify more pathogens from DFO, the 
IWGDF guidelines suggest sticking with conventional culture methods for the first-
line identification [33]. This is because of their lower cost, the lack of evidence of any 
benefit to covering the additional isolates identified and the potential for incurring 
the adverse effects of unnecessarily broad-spectrum antibiotic therapy. Practically, 
the only serology with a theoretical use for diagnosing DFO are anti-streptolysin 
antibodies for beta-hemolytic streptococci. If they are positive [34], the clinicians 
can (retrospectively) diagnose a streptococcal infection, which might be more useful 
in acute and severe soft tissue diabetic foot infections than in chronic DFOs.
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4. Microbiological therapy
4.1 Pathogens of DFO
Beside possible surgical intervention there is need for an antibacterial treat-
ment. Choosing an active agent is always first empirical, and subsequently targeted 
to the microbiological culture results. Knowledge of the possible microorganisms 
is a precondition to an empirical therapy [35]. Dependent on the country, most 
isolates of DFO are Staphylococcus aureus, β-hemolytic streptococci, coagulase-
negative staphylococci and Gram-negative pathogens such as Pseudomonas 
aeruginosa [36, 37]. Interestingly, the location of the infection is critical as well, 
so are calcaneal infections associated with P. aeruginosa in diabetic patients [19]. 
Unfortunately, despite the advocated greenish color of superficial Pseudomonas 
infections and a presumed characteristic smell of the infected wound, even long-
standing clinicians cannot predict the presence of P. aeruginosa by visual and 
olfactory means alone. The microbiological laboratory assessment is still necessary 
[38]. Multi-resistant pathogens in DFO are increasing in frequency worldwide 
[39] such as extended-spectrum beta-lactamase-producing Gram-negative rods 
(ESBL). Compared to DFI without involvement of the bone a meta-analysis found 
a three times higher chance in DFO for isolating a multi-resistant pathogen [40]. 
Fungi are rarity. Enterococci are equally rare but relatively more prevalent in the 
infected diabetic foot compared to other osteoarticular infections in the body such 
as steptococci and staphylococci [41, 42]. It is important to recognize that in the 
DFO patient, we may retrieve any bacteria, including avirulent coagulase-negative 
staphylococci and corynebacteria. Unlike to other infections such as pneumonia or 
endocarditis, the causative pathogens can also change during the current therapy of 
DFO, by selection of new (more resistant) pathogens by the therapeutic antibiotics 
and iterative surgeries during treatment. Therefore, if ever there is surgery during 
ongoing systemic antibiotic treatment, we recommend to re-sample again. The 
incidence of such a new microbiological finding can be as high as 10% [43].
4.2 Antibiotic therapy
The systemic antibiotic therapy is – next to a possible surgery, iterative profes-
sional debridement, (podiatric) wound care, enhancement of the patient’s compli-
ance, and off-loading – always required, if the goal is the healing of DFO. A clear 
recommendation for a specific antimicrobial agent, or the general administration 
route, cannot be made. A lot of studies and meta-analyses failed to show a supe-
riority of one specific drug against the others [44]. During the initial empirical 
treatment, we recommend to cover S. aureus. If the therapy fails to achieve a proper 
reduction of local inflammatory symptoms, then the therapy should be broadened 
to include (aerobic and anaerobic) Gram-negative bacteria [45]. In severe infec-
tions, (sub)tropical regions, or sepsis, a relatively broad empirical coverage target-
ing the local epidemiology of Gram-negative pathogens could be chosen [46] from 
the start. Further there is few data supporting parenteral therapy [47]. Of note, 
the microbiological culture results can lead to necessity of parenteral agents due to 
resistant pathogens.
Ideally, the DFO therapy is accompanied by professional debridement, or 
the resection of necrotic and infected bone (total amputation). A study of 50 
patients with chronic toe DFO showed that patients with surgical resections had 
a significantly lower relapse rate. This was also witnessed in single-center survey 
with partial amputations [48]. In well-selected patients and neuropathic DFO 
cases without progressive ischemia, other studies report successful treatment 
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without surgery, with selected remission rates of 60–70% [49, 50]. When surgery 
is not necessary for various reasons, a strictly conservative antibiotic therapy 
is very reasonable. Of note, the proportion of antibiotic-related side effects in 
randomized-controlled DFO trials may compromise up to 20–30% of all systemic 
antibiotic DFO regimens [49–55].
4.2.1 Biofilms
Clinicians often neglect the substantial role of bacterial biofilm in various 
infections, including the diabetic foot [35, 51]. Biofilm-forming bacteria are more 
refractory to host response and medical treatment and may be responsible for 
chronicity and complications. The proportion of biofilm-forming bacteria in DFO 
has been estimated at 30–60% [51]. In a clinical and microbiological study from 
Turkey [52], the assessed proportion of suspected biofilms among 339 diabetic foot 
wound isolates occurred in 34%. The multivariate regression analysis revealed two 
variables to be significant factors associated with biofilm: MDR micro-organism 
and XDR micro-organism [52]. New strategies are required in the management of 
wounds with biofilm to effectively destroy and even to prevent its formation.
One antibiotic might be associated with better outcomes in treating DFO 
biofilms: rifampin [53]. In analogy to implant-related staphylococcal infections, the 
antibiotic combination with rifampin may reveal a superior outcome. For example, 
Senneville et al. published a non-randomized observational study in 17 DFO 
patients treated with ofloxacin-rifampicin and achieved a remission in 88% of the 
cases [54]. Many other examples, especially from the US and France, are reported. 
We need the confirmation of the benefit of rifampicin use in DFO in future 
prospective-randomized trials.
4.3 Duration of antibiotic therapy
Because of a substantial risk for clinical failures according to every day’s clinical 
experience, many physicians treat DFOs, on purpose, with a very long course of 
antimicrobial therapy, although guidelines limit the overall antibiotic prescription 
to 4–6 weeks only [33, 55]. Of note, this official guidance never had advocated 
a prolonged course. A retrospective evaluation with 1018 episodes of soft tissue 
infections and DFO failed to determine an optimal duration of systemic antibiotic 
administration regarding the remission, or failure, of diabetic foot infection [48]. 
A randomized controlled trial found that 6 weeks, compared with 12 weeks, of tar-
geted antibiotic DFO therapy produced similar results [56]. This opinion is shared by 
other research groups [57, 58]. Today, a maximal duration of 6 weeks is the standard. 
If the is no remission after this period, clinicians should consider a new approach, 
which is surgical in the majority of cases. Maybe, the actual standard of 6 weeks 
might equally be too long for usual DFO cases. Recently, we published our experi-
ence of a randomized, controlled (RCT) pilot trial investigating shorter antibiotic 
administrations for DFO [55]. In this trial, a systemic antibiotic therapy of 3-weeks 
gave similar (and statistically non-inferior) incidences of remission and adverse 
events to a course of 6 weeks [55]. We also started the confirmatory RCT with 
400 planned episodes in the Balgrist University Hospital in Zurich [59], by using a 
streamlined surgical approach, an initial radiological examination by magnetic reso-
nance imaging and stratification between surgical versus totally antibiotic treatment 
approaches. If we confirm our pilot findings, the clinical implications, especially for 
improved antibiotic stewardship of in the field of DFO [60] might be substantial. 
Until further results are present, we agree with recommendations of up to six weeks 
of antibiotic therapy when residual infected bone is suspected or proven [25, 61–66].
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4.3.1 Serum inflammatory parameters during the follow-up control of therapy
Clinicians frequently control serum C-reactive protein (CRP) levels during 
the therapy of DFO. This routine practice should be abandoned. There is often no 
immediate benefit. On the contrary, surprisingly high CRP blood levels usually 
trigger unnecessary exams (X-rays, angiology exams, superficial wound swabs, 
urinary cultures); even in absence of clinical indications. The worst consequence 
would be a prolongation of the scheduled antibiotic therapy, only basing on these 
CRP level. In our prospectively collected database [55], routine serum CRP sam-
ples, at different time points during ongoing antimicrobial therapy for (operated) 
DFO, failed to predict future clinical failures [58].
4.3.2 Duration of antibiotic therapy after surgical resection of DFO
After a complete surgical resection of all infected and necrotic bone, many 
experts only warrant a short very duration of antimicrobial therapy (2–5 days) to 
finish with a remaining soft tissue infection [18, 59, 60]. However, surgeons fre-
quently doubt about the clinical absence of residual bone infection in the proximal 
amputation stump [63–65]. The IWGDF recommends sampling the marginal, 
remaining bone for evidence of residual infection; and advocates a up to 6 weeks of 
a consecutive, targeted antimicrobial therapy if the residual bone samples return 
with positive microbiological results [33]. This recommendation is cautious. We 
reported 482 DFO episodes with a median follow-up of two years after presumably 
curative total amputation [18]. According to this experience, neither the duration of 
the postsurgical antibiotic use, nor its immediate discontinuation, predicted future 
clinical failure [18]. Other research groups advocate that 5 days of a post-surgical 
antibiotic continuation are sufficient for a potential residual bone infection after 
amputation [64]. The residual cultures may also be false-negative, when receiving 
antibiotics, or false-positive when the samples are contaminated [33]. For example, 
colleagues from Basel, Switzerland, suggested that positive cultures, without a 
visual clinical confirmation of osteomyelitis and without concomitant histological 
confirmation, might overestimate the true rate of residual osteomyelitis, because of 
contamination at the time of surgery [66].
4.4 Administration route of antibiotic therapy
During the last decades, clinicians used a weeks’-long parenteral antibiotic 
therapy for all severe or moderate cases of DFO, usually with a switch to oral 
administration the hospitalized patient has been improving [67]. Today, we are 
living a change of paradigm in daily clinical life and start to consider oral regimens 
as efficacious as intravenous therapy in chronic DFO [48, 55, 67]. Therapy with oral 
antibiotic drugs is effective in non-bacteremic mild and moderate DFOs. A review 
of 93 DFO cases strongly supports the possibility of oral antibiotic regimens right 
from the start [68]. The same principle applies for other forms and localizations 
of chronic osteomyelitis [67]. Additional retrospective and prospective studies 
demonstrated the non-inferiority of oral antibiotic medication for DFO [60]. In 
our single-center cohort with a defined clinical diabetic foot infection pathway, oral 
β-lactam therapy did not alter the incidence of remission [67]. Spanish researchers 
conducted a prospective-randomized trial in DFO patients; with a strictly conser-
vative antibiotic treatment of ninety days versus an approach with surgery plus 
antibiotics of ninety days. In the conservative arm, oral antibiotics were given very 
early in the course. Practically, the outcomes were equivalent [61]. The authors of 
this chapter ignore the existence of a prospective-randomized trial in favor of a long 
Plea e us  Adobe Acrobat Reader to read this book chapter for free.
Just open this same document with Adobe Reader.
If you do not have it, you can download it here.
You can freely access the chapter at the Web Viewer here.
Securing Connection...Acrobat is locking documen loading.com
r
File cannot be found.
7
Diabetic Foot Osteomyelitis: Frequent Pathogens and Conservative Antibiotic Therapy
DOI: http://dx.doi.org/10.5772/intechopen.98328
initial parenteral treatment for chronic, non-septic, DFO in adult patients. Finally, 
topical antibiotics have no place in the treatment of unresected, deep DFO [69].
4.5 Antibiotic stewardship and clinical pathways
DFO’s are probably among the most frequent diseases leading to antibiotic 
overuse [60]. We think that the principles of antibiotic stewardship should also 
concern DFOs. We reviewed the literature on DFO [60] to assess the value of antibi-
otic stewardship in the management of DFO. According to this review, the three most 
effective measures could be: correct diagnosis of bone infection; use of antibiotic 
regimens with the narrowest spectrum; and, limiting the duration of antimicrobial 
treatment. Clinical pathways have been instituted for DFOs [70]. A multidisciplinary 
management regularly showed a significant reduction in amputation risks [71]. 
However, these multidisciplinary teams have also their limitations: 1) it is difficult 
to bring the team members together; 2) the number of patients requiring evaluation 
often exceeds the capacity of fixed regular meetings; 3) the meetings are time-
consuming and key members may be absent. Theoretically, order-sets (especially if 
they are embedded within interactive electronic websites) [12] are tools to implement 
“bundles” of approaches and, hopefully, improve outcomes. However, the academic 
experience of these order sets must be further evaluated, especially in resource-poor 
settings. There are also many administrative approaches that might improve anti-
biotic stewardship in DFO. Governments can initiate diabetic foot centers [72], or 
regular workshops and public educational lectures. The access to regional or interna-
tional guidelines must be encouraged [60].
5. Possible future research
We need many prospective, clinical trials targeting the reduction of unnecessary 
(systemic and topical) antibiotic use, assessing the value of antibiotic stewardship 
programs, and developing evidence-based guidance. We should also be interested 
in microbiomes and new therapies. We want to target unanswered questions and 
advance research in all aspects of DFO. For example, regarding neo-vascularization, 
one future hope lies in stem cells. Knowing that a subset of human monocytes 
expresses TIE-2, we could enhance neovascularization, since ischemia is a major 
concomitant problem to chronic DFO. We successfully extracted high numbers of 
proangiogenic TIE-2 monocytes from venous blood of diabetic patients without 
ischemia [73]. Likewise, current scientific achievements confirm the feasibility of 
amplifying adipose stem cells for angiogenesis from the abdominal fat of ischemic 
patients [74]. The implication of these findings in terms of autologous injections 
for therapeutic neo-angiogenesis will require further studies. DFO will remain a 
“never-ending challenge” [75].
6. Conclusions
We can treat DFO conservatively by (targeted) systemic antibiotic administra-
tion, proper wound debridement (if necessary), and adequate off-loading. With 
the conservative therapy, the progressive destruction of underlying bone can be 
arrested in probably 60–70% of episodes in well-selected, compliant patients 
without major bone destruction or advanced concomitant ischemia; at least for a 
short follow-up time. A clinical regular and close follow-up by specialized health-
care workers is paramount, since clinical failures on the long-term are frequent; 
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especially in the reason for the initial chronic DFO has not been reversed. The 
secondary prevention of further infection episodes is important. Any systemic 
antimicrobial agent is suitable, and very probably in oral administration form from 
the start (unless there is a concomitant severe clinical systemic inflammation, 
bacteremia or sepsis). The duration of antibiotic therapy is currently fixed to six 
weeks, but further trials and evaluations reducing the overall duration to lesser time 
spans are under way [59].
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